多系统缩中的震:一个系统的文献综述
Maria Schneller1, Frank Jagusch2, Bianca Calio2
1Department of Neurology, Medical University of Graz, Graz, Austria.
Journal of neural transmission (Vienna, Austria : 1996)
|March 2, 2026
概括
震在多个系统缩 (MSA) 中很常见,并且根据亚型而异. 一个3赫兹的伪静止震特征MSA-C,而MSA-P显示姿势和休息震. 莱沃多巴可提供可变震改善.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 临床神经生理学 临床神经生理学
背景情况:
- 震影响多重系统缩 (MSA) 患者的高达80%,但其特征尚不清楚.
- 将MSA震与帕金森病 (PD) 等其他疾病区分开来,对于准确诊断至关重要.
- 在MSA中震的表型变异性需要详细的表征.
研究的目的:
- 为了确定MSA中震的流行率和特征.
- 分析MSA表型 (MSA-P和MSA-C) 和身体区域的震分布.
- 评估MSA震对各种治疗的反应能力.
主要方法:
- 系统地搜索PubMed的文献,寻找在MSA中报告震的研究,遵守PRISMA指南.
- 使用JBI批判性评估工具对符合条件的研究进行选,数据提取和偏差风险评估.
- 来自25项研究的数据审查,其中包括963名患有MSA的患者.
主要成果:
- 震的流行率和类型在MSA-P和MSA-C之间存在显著差异.
- MSA-C主要表现为~3Hz的伪静止震,而MSA-P显示为7-8Hz的姿势震和5-6Hz的休息震.
- 利沃多巴在11.8-92%的病例中改善了震,在MSA-P和动作震中效果更大.
结论:
- 震是多个系统缩中频繁和表型多样化的表现.
- 一个3赫兹的伪静止震是区分MSA-C.的一个关键特征.
- 对利沃多巴的治疗反应是可变的,这表明需要量身定制的治疗方法.
相关概念视频
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Myasthenia Gravis: Diagnostic Tests
2.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K


